Almeida-Pinto, Nísia
Dschietzig, Thomas Bernd
Brás-Silva, Carmen
Adão, Rui http://orcid.org/0000-0003-2203-436X
Funding for this research was provided by:
Fundação para a Ciência e Tecnologia (UIDB/00051/2020, UIDP/00051/2020, 2022.08921.PTDC)
European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant (Agreement No 847635)
Universidade do Porto
Article History
Received: 17 April 2023
Accepted: 4 September 2023
First Online: 18 September 2023
Declarations
:
: TBD is CEO of Relaxera, a pharmaceutical company developing relaxin-2 for transplantation medicine. The other authors declare no conflicts of interest.